Seasonal Influenza Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Seasonal Influenza Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight’s “Seasonal Influenza Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Seasonal Influenza, historical and forecasted epidemiology as well as the Seasonal Influenza market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock detailed insights into the Seasonal Influenza Market by downloading the comprehensive report from DelveInsight @ Seasonal Influenza Treatment Market Size
Key Takeaways from the Seasonal Influenza Market Report
- In September 2024:- ModernaTX Inc.- A Phase 3, Randomized, Observer-blind, Active-controlled, Case-driven Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared With a Licensed Inactivated Seasonal Influenza Vaccine in Adults ≥50 Years of Age. The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against protocol-defined influenza-like illness (ILI) caused by any influenza A or B strains.
- In 2023, as per DelveInsight’s assessment, 37 million medical visits related to seasonal influenza were estimated in the 7MM. These cases are projected to rise by 2034 at a CAGR of 0.3%.
- In the EU4 and UK , in 2023, Italy had the highest medical visits related to seasonal influenza with 5 million cases, followed by Germany with 4 million cases in the same year. On the other hand, Spain had the lowest medical visits of seasonal influenza as 833 thousand cases in 2023.
- The leading Seasonal Influenza Companies such as SAb Biotherapeutics, Inc., Emergo Therapeutics, Inc., AlloVir, Cocrystal Pharma, Poolbeg Pharma, Ridgeback Biotherapeutics, Viriom, Inc., NanoViricides, Evrys Bio, ETHRIS, Kino Pharma, and others.
- Promising Seasonal Influenza Therapies such as mRNA-1010, SAB-176, TETRALITE, mRNA-1345, and others.
Gain a competitive edge in the Seasonal Influenza Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Seasonal Influenza Treatment Drugs
Seasonal Influenza Epidemiology Segmentation in the 7MM
- Total Medical visits related to Seasonal Influenza
- Total Seasonal Influenza Hospitalized Cases
- Seasonal Influenza Type-specific Cases
- Seasonal Influenza Vaccination
Seasonal Influenza Market Insights
Seasonal Influenza spreads through respiratory droplets and is very contagious, and most people can receive at- home care for the flu. Symptom relief may be achieved by combining lifestyle changes with over-the-counter medications. Patients not from a high-risk group can be managed with symptomatic treatment whereas, patients with severe or progressive clinical illness associated with suspected or confirmed influenza virus infection (i.e., clinical syndromes of pneumonia, sepsis, or exacerbation of chronic underlying diseases) can be treated with the antiviral drug. Prophylactic treatment is part of the treatment for influenza.
Discover key developments and opportunities in the Seasonal Influenza Market. Click here to learn more from DelveInsight’s latest report @ Seasonal Influenza Market Size
Seasonal Influenza Marketed Therapies
- XOFLUZA (baloxavir marboxil): Genentech/Roche
XOFLUZA is a first-in-class, single-dose oral medicine with an innovative proposed mechanism of action that has demonstrated efficacy in a wide range of influenza viruses, including in vitro activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies.
- FLUZONE QUADRIVALENT /VAXIGRIP TETRA: Sanofi
FLUZONE QUADRIVALENT is a quadrivalent inactivated influenza vaccine produced in the US, containing two Type A antigens and two Type B antigens to provide increased protection against more circulating strains of influenza viruses.
Seasonal Influenza Emerging Therapies
- SAB-176: SAb Biotherapeutics, Inc.
SAB-176 is a multivalent, broadly neutralizing fully human polyclonal antibody therapeutic candidate developed by SAb Biotherapeutics that leverages the human biological immune response in developing the treatment of hospitalized patients with severe seasonal influenza.
Seasonal Influenza Emerging Vaccines
- mRNA-1010: ModernaTX, Inc.
mRNA-1010 is Moderna’s first seasonal influenza mRNA vaccine candidate to enter the clinic. The mRNA-1010 is a quadrivalent vaccine candidate that encodes for hemagglutinin glycoproteins of the four influenza strains recommended by the WHO for the prevention of influenza, including influenza A/H1N1, A/H3N2, and Influenza B/Yamagata- and B/Victoria-lineages.is Moderna’s first seasonal influenza mRNA vaccine candidate to enter the clinic.
Seasonal Influenza Market Outlook
Seasonal Influenza spreads through respiratory droplets and is very contagious, and most people can receive at-home care for the flu. Symptom relief may be achieved by combining lifestyle changes with over-the-counter medications. Patients not from a high-risk group can be managed with symptomatic treatment whereas, patients with severe or progressive clinical illness associated with suspected or confirmed influenza virus infection (i.e., clinical syndromes of pneumonia, sepsis, or exacerbation of chronic underlying diseases) can be treated with the antiviral drug. Prophylactic treatment is part of the treatment for influenza.
Download DelveInsight’s Seasonal Influenza Market report today and stay ahead in this rapidly evolving field. @ Seasonal Influenza Clinical Trials
Scope of the Seasonal Influenza Market Report
- Coverage- 7MM
- Seasonal Influenza Companies- SAb Biotherapeutics, Inc., Emergo Therapeutics, Inc., AlloVir, Cocrystal Pharma, Poolbeg Pharma, Ridgeback Biotherapeutics, Viriom, Inc., NanoViricides, Evrys Bio, ETHRIS, Kino Pharma, and others.
- Seasonal Influenza Therapies- mRNA-1010, SAB-176, TETRALITE, mRNA-1345, and others.
- Seasonal Influenza Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Seasonal Influenza Unmet Needs, KOL’s views, Analyst’s views, Seasonal Influenza Market Access and Reimbursement
Download the report to understand which factors are driving Seasonal Influenza Market Trends @ Seasonal Influenza Market Trends
Table of Content
1. Key Insights
2. Report Introduction
3. Seasonal Influenza Market Overview at a Glance
4. Seasonal Influenza Market: Future Perspective
5. Executive Summary of Seasonal Influenza
6. Key Events
7. Disease Background and Overview: Seasonal Influenza
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Drugs
11. Marketed Vaccines
12. Comparative Analysis
13. Emerging Therapies
14. Emerging Vaccines and Prophylactic Agents
15 Seasonal Influenza: Seven Major Market Analysis
16. Key Opinion Leaders’ Views
17. Seasonal Influenza Market Drivers
18. Seasonal Influenza Market Barriers
19. Seasonal Influenza Market Unmet Needs
20. SWOT Analysis
21. Market Access and Reimbursement
22. Appendix
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/